All In Biotech

Drug Trial Radar · NCT07712913

Extended-release Pregabalin for the Treatment of Neuropathic Pain in Patients With Diabetic Peripheral Neuropathy and Postherpetic Neuralgia

A Phase III, Multicenter, Randomized, Double-blind, Double-dummy, Controlled, Parallel-group, Non-inferiority Clinical Trial to Evaluate the Efficacy and Safety of Extended-release Pregabalin Tablets Compared With Immediate-release Pregabalin Tablets, in the Relief of Neuropathic Pain in Participants With Diabetic Peripheral Neuropathy or Postherpetic Neuralgia.

Last checked: Nov 20, 2026Latest source record: Jul 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 348 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

348

Planned (sponsor's estimate)

Start

Jun 18, 2026

Primary completion

Jun 1, 2027

Study completion Jun 1, 2027

Sponsor

Sponsor type
Industry
First posted
Jul 20, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Extended-release Pregabalin for the Treatment of Neuropathic Pain in Patients With Diabetic Peripheral Neuropathy and Postherpetic Neuralgia

Conditions

  • Diabetic Neuropathy
  • Neuropathic Pain
  • Neuralgia, Postherpetic

Interventions

  • Experimental: Pregabalin XRDrug

    Pregabalin XR: extended-release tablet, with an initial dose of 82.5 mg once daily. The dose may be adjusted every 7 days during the first 4 weeks of treatment, up to a maximum of 660 mg once daily. In addition, the experimental group will receive a placebo twice daily.

  • Comparator: Dorene TabsDrug

    Pregabalin immediate-release tablets, at an initial dose of 75 mg twice daily. The dose may be adjusted every 7 days during the first 4 weeks of treatment, up to a maximum of 300 mg twice daily. In addition, the comparator group will receive a placebo once daily.

  • Comparator placeboDrug

    Comparator placebo

  • experimental placeboDrug

    experimental placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Difference in the mean pain intensity score 16 weeks after the start of treatment, compared to baselineTime frame: 16 weeks

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • Cpec Obras Sociais Irmã Dulce

    Salvador, Estado de Bahia, Brazil · Recruiting

  • Instituto Anima de Extensão Universitária - Unibh

    Belo Horizonte, Minas Gerais, Brazil · Recruiting

  • Centro de Ensino Superior de Vespasiano

    Vespasiano, Minas Gerais, Brazil · Recruiting

  • Instituto Estadual Do Cerebro Paulo Niemeyer

    Rio de Janeiro, Rio de Janeiro, Brazil · Recruiting

  • Apec Sociedade Potiguar de Educação E Cultura

    Natal, Rio Grande do Norte, Brazil · Recruiting

  • Clinica Neurologica E Neurocirurgica de Joinville

    Joinville, Santa Catarina, Brazil · Recruiting

  • Instituto Anima de Extensão Universitária - Unisul

    Palhoça, Santa Catarina, Brazil · Recruiting

  • Casa de Nossa Senhora Da Paz Ação Social Franciscana

    Bragança Paulista, São Paulo, Brazil · Recruiting

  • Synvia Campinas

    Campinas, São Paulo, Brazil · Recruiting

  • Trialstar Campinas

    Campinas, São Paulo, Brazil · Recruiting

  • Synvia Clinical Barra Funda

    São Paulo, São Paulo, Brazil · Recruiting

  • Iscp Sociedade Educacional

    São Paulo, São Paulo, Brazil · Recruiting

  • Fundação de Beneficência Hospital de Cirurgia

    Aracaju, Sergipe, Brazil · Recruiting

  • Associação Aracajuana Hospital Santa Isabel

    Aracaju, Sergipe, Brazil · Recruiting

  • Newdata Clinical Research

    Aracaju, Sergipe, Brazil · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.